Back to results
US 2012/0252853 A1Published application
Positive allosteric modulators of nicotinic acetylcholine receptor
AssigneeH. Lundbeck A/S
InventorsAnette Graven Sams, Jørgen Eskildsen, Jesper Frank Bastlund
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine α7 receptor.
Claims15
A compound according to formula I
- wherein R1 represents H, trifluoromethyl, difluoromethyl, C1-4alkyl, C2-4alkenyl or C2-4alkynyl;
- R2 represents H, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, halogen or cyano, wherein said C1-4alkyl, C2-4alkenyl or C2-4alkynyl is optionally substituted with one or more substituents selected from chlorine and fluorine;
- R3, R4, R5 and R6 are selected independently from H, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, halogen and cyano, wherein said C1-4alkyl, C2-4alkenyl or C2-4alkynyl is optionally substituted with one or more substituents selected from chlorine and fluorine;
- R7 represents H, methyl, trifluoromethyl or hydroxymethyl;
- Q represents a heteroaryl with 5 ring atoms, wherein 1, 2 or 3 ring atoms are selected independently from O, N and S, wherein said heteroaryl may be optionally substituted on its carbon atoms with one or more substituents represented by R10, and provided that said heteroaryl cannot be 1,2,3 triazolyl or imidazolyl;
- each R10 is independently selected from C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4-fluoroalkoxy, halogen and oxo, wherein said C1-4alkyl, C2-4alkenyl or C2-4alkynyl is optionally substituted with one or more substituents selected from fluorine, C1-4alkoxy and C1-4fluoroalkoxy;
- if one or more ring atoms in said heteroraryl are N atoms these may, when valency allows, individually be optionally substituted with a substituent represented by R11, wherein each R11 is independently selected from C1-4alkyl and a monocyclic saturated ring moiety having 4-6 ring atoms wherein one of said ring atoms may be O and the rest is C, and wherein said C1-4 alkyl may be optionally substituted with one or more substituents selected from fluorine, C1-4alkoxy and C1-4fluoroalkoxy;
- when Q is a pyrazolyl at least one of the N atoms in said pyrazolyl must be substituted with R11;
- two R10 or one R10 and one R11 may, when sitting on neighbouring ring atoms and when represented by C1-4alkyl or be linked together by a carbon bond to form a fused ring system;
- or a pharmaceutically acceptable salt thereof;
- with the proviso that the compound of formula [I] is other than
- furan-2-carboxylic acid (2-methyl-1H-indol-5-ylmethyl)-amide;
- furan-2-carboxylic acid (1,2-dimethyl-1H-indol-5-ylmethyl)-amide;
- thiophene-2-carboxylic acid (1,2-dimethyl-1H-indol-5-ylmethyl)-amide;
- thiophene-2-carboxylic acid (2-methyl-1H-indol-5-ylmethyl)-amide.
12 more elements
Dependencies are inferred from the claim text.